Clinical trials: Aromatase Inhibitors
Breast Cancer, Stiffness of Hand, Not Elsewhere Classified
Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer
RATIONALE: Acupuncture may help relieve joint stiffness related to aromatase inhibitors in patients with early-stage breast cancer.
- Trial name
- NCT05098951
- Testing
- Acupuncture
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Affiliated Hospital of Qinghai University
Endometriosis
Bay98-7196, Dose Finding / POC Study
Purpose of the study is to test efficacy and safety of BAY98-7196 intravaginal ring as a new treatment option for patients with endometriosis-associated pelvic pain
- Trial name
- NCT02203331
- Testing
- Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
- Where
- 117 sites in United States, Austria and 12 more
- Volunteers
- 319 people
- Sponsor
- Bayer
Breast Cancer
Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain
Researchers at the John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center (PSJHC) are trying to examine whether acupuncture reduces joint pain in patients being treated with aromatase inhibitor (AI) therapy…
- Trial name
- NCT02548637
- Testing
- Acupuncture Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Saint John's Cancer Institute
Breast Cancer, Breast Cancer Metastatic
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)
This study evalues the efficacy -as determined by the clinical benefit rate (CBR)- of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring…
- Trial name
- LUZERN (NCT04240106)
- Testing
- Niraparib, Aromatase Inhibitors
- Where
- 10 sites in Spain
- Volunteers
- 14 people
- Sponsor
- MedSIR
Musculoskeletal Symptoms, Breast Cancer
AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial
This study aims to develop and evaluate an artificial intelligence (AI)-based skeletal recognition system designed to support real-time, interactive rehabilitation exercise (RE programs.
- Conditions
- Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy, Aromatase Inhibitors
- Trial name
- AiRE-MS (NCT06642948)
- Testing
- Motor rehabilitation based on ai visual recognition
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Breast Cancer, Adherence, Medication
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer
Breast cancer is the most common malignancy in women, with HR+/HER2- early breast cancer accounting for approximately 70% of cases.
- Trial name
- riboADHERE (NCT07630948)
- Testing
- Adherence package consisting of additional education and adherence reminders
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer, Bone Diseases
Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption
Aromatase inhibitors are potent suppressors of breast cancer growth, but side effects include bone loss, fractures, arthralgias and myalgias.
- Trial name
- NCT00904423
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mark Pegram
Arthralgia
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body.
- Trial name
- NCT00111241
- Testing
- aromatase inhibitors (letrozole, anastrozole)
- Where
- Australia
- Volunteers
- 115 people
- Sponsor
- Monash University
Breast Cancer, Hormone Receptor Positive Tumor
Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA)
In this phase II, multicenter, self-controlled clinical trial, we will evaluate the safety and efficacy of OPERA® for treating anti-aromate inhibitors (AIs) induced arthralgia.
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Arthralgia
- Trial name
- AIA (NCT04161833)
- Testing
- OPERA
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Muscle Pain, Joint Pain
Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors
The Purpose of this study is to determine whether vitamin D3 supplements will decrease the muscle and bone pain that are reported by women who take Aromatase Inhibitors.
- Trial name
- NCT01509079
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- HealthPartners Institute
Advanced Breast Cancer
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)
The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease.
- Trial name
- HERMIONE-7 (NCT04227327)
- Testing
- Abemaciclib, Aromatase Inhibitors
- Where
- 39 sites in Italy
- Volunteers
- 31 people
- Sponsor
- University of Milano Bicocca
Breast Cancer, Medication Adherence
Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors
The proposed research is a randomized controlled investigation of the efficacy of motivational interviewing (MI) to improve adherence to aromatase inhibitors (AI) in a community sample of patients with poor adherence to AIs.
- Trial name
- MI for AIs (NCT02883361)
- Testing
- Motivational enhancement therapy, Attention Control
- Where
- Canada
- Sponsor
- University of Calgary
Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer
Personalised Disease Monitoring in Metastatic Breast Cancer
Patients with metastatic breast cancer may respond well to treatment and metastases can remain stable for several years. Despite personalised medicine being increasingly used for diagnosis and treatment, follow-up still include…
- Trial name
- PDM-MBC (NCT04597580)
- Where
- 7 sites in Sweden, United Kingdom
- Volunteers
- 97 people
- Sponsor
- The Christie NHS Foundation Trust
Fertility
Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women
A single center, open label randomized clinical trial designed to examine ovarian follicular dynamics following attempted atresia induction during the late follicular and early luteal phase of the menstrual cycle using an…
- Trial name
- NCT01046578
- Testing
- Letrozole
- Where
- Canada
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Breast Neoplasms
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
This non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer…
- Trial name
- CAROLEEN (NCT06830720)
- Testing
- ribociclib + AI ± LHRH, abemaciclib + ET ± LHRH, ET mono ± LHRH
- Where
- 287 sites in Austria, Germany
- Volunteers
- 3,250 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
This study is designed to evaluate the clinical effects of the addition of metronomic oral vinorelbine to letrozole and anastrozole.
- Trial name
- VICTORIANE (NCT02730091)
- Testing
- Letrozole, Anastrozole, Vinorelbine
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
PCOS (Polycystic Ovary Syndrome), Infertility
Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)
This randomized clinical trial aims to compare the efficacy and safety of extended letrozole therapy (5 mg/day for 10 days) versus standard letrozole therapy (5 mg/day for 5 days) for ovulation induction in women with polycystic…
- Conditions
- PCOS (Polycystic Ovary Syndrome), Infertility, Anovulation
- Trial name
- PROLEx-PCOS (NCT07159880)
- Testing
- Traditional Letrozole Therapy, Extended Letrozole Therapy
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GABRIEL MONTEIRO PINHEIRO
Vasomotor Symptoms (VMS)
Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.
- Trial name
- NCT04080297
- Testing
- oral capsule of Q-122
- Volunteers
- 21 people
- Sponsor
- Que Oncology
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
This clinical trial evaluates if in-person acupuncture or virtual acupressure therapy prevents aromatase inhibitor-associated joint pain in Non-Hispanic Black postmenopausal women with stage I-III (early-stage) hormone receptor…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
- Trial name
- NCT06534125
- Testing
- Acupressure Therapy, Acupuncture Therapy, Aromatase Inhibition Therapy
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- Emory University
Metastatic Breast Cancer
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
To demonstrate the efficacy of sabizabulin in the treatment of ER+HER2- metastatic breast cancer (MBC) as measured by progression free survival (PFS) by RECIST v1.1.
- Trial name
- NCT05079360
- Testing
- Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
- Where
- 26 sites in United States
- Sponsor
- Veru Inc.